Healthcare Industry News: Alzheimer's
News Release - January 18, 2007
Neuroptix Expands Executive Team, Adds Evan Sherr as Vice President, Product Management, and Vincent Valvo as Vice President, Engineering and Product DevelopmentPioneer in Non-Invasive Optical Scanning Diagnostics for Alzheimer's Brings on Board Longtime Life Sciences Executives as Company Ramps up Operations
ACTON, Mass.--(HSMN NewsFeed)--Neuroptix Corporation, a Massachusetts-based pioneer in the early detection of Alzheimer's disease through non-invasive laser eye scanning, today announced that two longtime life sciences executives have joined the company's expanded management team, with Evan Sherr signing on as Vice President, Product Management, and Vincent Valvo taking on Vice President, Engineering and Product Development duties.
Paul Hartung, President and CEO of Neuroptix, said, "We are delighted to have two highly experienced industry executives such as Evan and Vincent join Neuroptix at this very exciting time for us. With the tremendous preclinical and business advances we've made in the past year, we look forward to their contributions and leadership as Neuroptix's operations begin to expand."
Evan Sherr, Vice President, Product Management
Evan Sherr is responsible for the areas of Product Management and Clinical Development. Prior to joining Neuroptix, he was Executive Director of Clinical Research and Development and Executive Director of Surgical Business at Cynosure for the last 10 years, responsible for their surgical business unit and clinical department. He also managed development and commercialization of dermatology, otolaryngology, gastrointestinal, orthopedic and ophthalmology products. Mr. Sherr has extensive experience in business development, including creating a strategic alliance with Pentax Corporation, resulting in a new product and market initiative. Prior to Cynosure, he was a Research and Development Scientist at Summit Technology.
Vincent Valvo, Vice President, Engineering and Product Development
Vincent Valvo is responsible for technical project management, product development, and software engineering. He has twenty-five years of leadership experience in product development of embedded real-time medical devices, data management systems and networking products.
Prior to joining Neuroptix, Vincent was CEO of V Squared Computing, a medical software development and project management company that he founded, whose customers included pharmaceutical, chemistry and cardiology companies and research institutions.
Before his tenure as CEO of V Squared, Vincent was Vice President of Research and Development at Aurora Technologies, an engineering company that developed connectivity products. At Bayer Diagnostics, Vincent served as Software Development Manager, where he directed the software development for blood gas analyzers and laboratory data management products. Before Bayer, Vincent was Principal Software Engineer at CardioData Corp., a startup company that developed ambulatory EKG analysis instruments and data management systems, which were used for major international drug studies and clinical diagnostics.
About Neuroptix Corporation
Founded in 2001, Neuroptix develops, manufactures and distributes state-of-the-art products for extremely sensitive measurements of biophysical changes in the eye, including non-invasive instruments for diagnosis and monitoring Alzheimer's disease undergoing clinical development. Adaptable and innovative, Neuroptix's products are designed for a variety of research environments including academic and pharmaceutical laboratories. Neuroptix is also developing diagnostic agents for application in screening tests for Alzheimer's disease and prion diseases. For more information, contact email@example.com or visit the web site at www.neuroptix.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.